胰高血糖素样肽-1受体激动剂与肿瘤相关性的研究进展  

Advances in the correlation between glucagon-like peptide-1 receptor agonists and tumors

作　　者：杨文勇 李鹏杰[1] 王驰[1] 项莹[1] YANG Wenyong;LI Pengjie;WANG Chi;XIANG Ying(Department of Endocrinology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2021年第2期355-358,共4页Journal of Modern Oncology

摘　　要：我国糖尿病和肿瘤防治工作均面临着严峻挑战。有研究显示2型糖尿病患者与普通患者相比有更高的肿瘤发病率。胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂因其减轻体重、保护胰岛β细胞、心血管获益以及副作用小等特点广泛用于2型糖尿病治疗。人体多个组织和器官均表达GLP-1受体,因此GLP-1受体激动剂在糖尿病患者中广泛应用对各肿瘤的发生、发展和转归备受关注,本文就GLP-1受体激动剂与各肿瘤的相互关系作一综述。Diabetes and tumor prevention and treatment in China are facing severe challenges.Studies have shown that type 2 diabetes patients have a higher incidence of tumors than the general population.Agonists of glucagon-like peptide-1(GLP-1)are widely used in the treatment of type 2 diabetes due to their characteristics of weight loss,protection of beta cells of the pancreas,cardiovascular benefits,and minimal side effects.GLP-1 receptor is expressed in many tissues and organs of the human body,so GLP-1 receptor agonist is widely used in diabetic patients,which has attracted much attention on the occurrence,development and prognosis of various tumors.This paper reviews the relationship between GLP-1 receptor agonist and various tumors.

关 键 词：胰高血糖素样肽-1 受体激动剂 肿瘤 

分 类 号：R730[医药卫生—肿瘤]